The objective of this study is to understand how university students use generative AI tools like ChatGPT, Gemini, and others when engaging in writing tasks, whether personally (e.g., writing emails) or academically (e.g., completing assignments), and how their cognitive processes work with these tools.

This study aims to understand how university students interact with generative AI tools like ChatGPT, Gemini, and others in writing tasks, both personally (e.g., writing emails, cover letter) and academically (e.g., completing assignments). We will conduct 1) brief demographic survey 2) interviews and 3) think-aloud sessions with students to understand how generative AI tools are used in writing.

$40

This is a quantitative study investigating the relationship between family functionality, substance use, and mental health among a population of emerging adults.

You will take a brief survey.

This is a Phase 2b clinical research study, which is investigating the use of 5-Aminolevulinic Acid (5-ALA) combined with a Low-Intensity Diffuse Ultrasound (LIDU) system for Sonodynamic Therapy (SDT) in patients with newly diagnosed glioblastoma. LIDU is the name of the investigational SDT device developed by Alpheus Medical. SDT includes the combination of a sonosensitizing drug, also known as a sonosensitizer, that will only be absorbed by tumor cells, and ultrasound to activate the sonosensitizer and cause damage to the tumor cells. The SDT tested in this study includes the oral drug 5-Aminolevulinic Acid (5-ALA) as an investigational sonosensitizer. This investigational treatment is being tested as a potential treatment for your cancer, SDT has been shown in previous cell and animal studies to potentially have an anti-cancer effect.

In this research study there will be two treatment groups. One treatment group will receive standard of care maintenance temozolomide with 5-ALA + SDT, you will have a 50% of receiving this treatment group. The other treatment group wll receive standard of care maintenance temozolomide with placebo, an oral solution that will look like and taste like 5-ALA but will have no active ingredients in it, and sham SDT, a program will be run on the SDT device that will look and sound the same, but will not deliver ultrasound, you will have a 50% chance of receiving this treatment group. If you are eligible for the study, and agree to participate you will be randomized, like the flip of a coin, to one of the two treatment groups, neither you nor your doctors will know which treatment group you have been assigned.

This trial is designed for patients who are newly diagnosed with multiple myeloma (MM) but who do not want or cannot have an autologous stem cell transplant. Teclistamab and talquetamab have been used alone along with other drugs in the treatment of MM. this study hopes to add either drug to a standard treatment for MM at time of diagnosis to see how effective it is in keeping the MM quiet conpared to standard treatment alone.

Participants must be willing to come to all clinic study visits. The first cycle of treatment the participant will be hospitalized to make sure they do not have any side effects. You will be treated every four weeks as an outpatient until the treatment no longer works. You should tell your study team all side effects you feel and all medication you are taking.

$54.00 per completed visit. A caregiver may receive compensation of the same amount.

The purpose of this study is to investigate the effects of replacing snacks high in saturated fats and added sugars with pecans on blood sugar control, heart health and diet quality in individuals with prediabetes. Participants will be randomized into one of two groups. Group 1 will consume 1.5 oz of pecans per day in place of normally consumed snacks high in saturated fat and added sugars for 16 weeks. Group 2 will be asked to continue consuming their current diet for 16 weeks. Measures will be taken to evaluate blood sugar, heart health and dietary intake at the beginning and 16 weeks later.

• The total time commitment for this study is approximately 4 months. It may take up to 7 months to complete the study from the time that you do the clinic screening visit. • During the study, we will ask you to consume 1.5 oz of pecans per day for 16 weeks, or to use provided gift cards to purchase and consume your usual snacks/diet. • You will be asked to come to the Penn State Research Kitchen on campus once a month for 16 weeks to pick up your pecans or gift cards. • We will draw blood from you several times during the study, once at screening, and on two consecutive days at the start and end of the study (total 5 times). • At the start and end of the study, we will also measure your blood pressure and perform non-invasive tests of artery health. • You will also be asked to wear a continuous glucose monitor (CGM) for 14 days—7 days before the first testing visit and 7 days at the end of the study. The CGM is a small sensor worn on your arm that measures your blood sugar every 15 minutes. You will need to attend a non-fasting visit to have the CGM fitted (2 visits total). • At the start and end of the study, we will ask you to collect 12 saliva samples over two days at home. • At the start and end of the study, we will collect a small hair sample from the back of your head. • You will also be asked to collect a stool sample at the beginning and end of the study (2 total). • Compensation for this study is up to $150

150

This study explores whether simple digital activities, such as watching short videos and answering easy questions, can help researchers understand early changes in memory, attention, and language. Participants will complete these tasks on a tablet, computer, or smartphone, either independently or with support. The study does not diagnose any condition. The goal is to learn whether everyday digital behaviors can provide early, low burden signals of cognitive change in older adults.

Participants will watch short and long videos on a tablet, computer, or smartphone and answer simple multiple-choice and short-answer questions about each video. They may also provide brief written or spoken explanations. The session takes about 20 to 40 minutes and can be completed independently or with researcher support. An optional second session may be completed after two to six weeks.

This study is being performed to make sure this medication helps people the way it's supposed to and to make sure it is safe. Within this study you will be assigned to 1 of 3 treatment arms, including 2 ritlecitinib dosage levels (50 mg and 30mg) and 1 placebo arm. You will be instructed to take your study medicine by mouth once a day for 24 weeks (approximately 6 months). In addition, to taking the study medication you will also need to attend in person visits within the research office at different time points throughout the study. Your total length of participation could last up to about 8 months.

Participants will be assessed for study eligibility at the screening visit after the informed consent form is reviewed, all questions have been answered, and the consent form has been signed. Should a participant qualify to participate in the research study they will attend 9 visits within the research office over approximately 28 weeks (7 months). At different time points throughout the study participants will have their hair examined, an ECG performed, a hearing test performed, blood drawn, and complete questionnaires. In addition to the study activities participants will be instructed to take their study medicine by mouth once a day and as directed by the study team.

To see if the combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus SoC chemotherapy plus trastuzumab plus pembrolizumab is better in treating gastric or gastroesophageal junction cancer

Participants will need to come to the clinic twice before they are able to start study treatment. The first time is to sign a consent form allowing their tumor tissue that has been stored to be spent for testing. This test will look to see if the tissue has changes in it to see if the medication will work. If the tissue has the receptive changes a second consent form will be signed to participate in the study. You will need to have tests done to make sure it is safe for you to participate in the study. If the tests results determine that is it safe, you will begin treatment. The first month of treatment you will need to come to the clinic every week for blood tests and to see how you are feeling. After that you will need to come to the clinic once a month for treatment and blood tests. You will also have scans done at certain time in the study. Those scans will tell the doctor if the study treatment is working to make your cancer go away. You will stay on this treatment until it stops working. After that, you will come back to the clinic for two more visits to see how you are feeling.

To evaluate the long-term safety of AAV2-hAQP1 in participants with radiation-induced late xerostomia

Participants who were on the parent trial and did not receive actual drug will be invited to be treated and then rolled over into long term follow up. For those who were treated with actual drug will roll over into a long term follow up. Long term follow up participants will be followed up monthly for 5 years.

$60 per visit

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Arm A: Patients receive triptorelin intramuscularly (IM) up to 14 days prior to standard chemotherapy. For patients whose chemotherapy exceeds 24 weeks, a second dose of triptorelin may be given 24 weeks after the first dose at the treating physician's discretion. Patients also undergo blood sample collection throughout the study. Arm B: Patients receive standard chemotherapy. Patients also undergo blood sample collection throughout the study.

A blood sample taken for the study; about 15 mL (one tablespoon of blood) will be drawn at each of these four times: before cancer treatment begins; at the end of cancer treatment;1 year after the end of cancer treatment; 2 years after the end of cancer treatment.

This is a drug study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL).

All subjects on study will be treated with the medicine blinatumomab. Some subjects will also receive an additional medicine, nivolumab. Subjects will receive treatment on this study for about 1.5-2.5 months. Treatment is divided into 1-2 cycles. Before the start of therapy, patients will have a bone marrow evaluation for Immunophenotyping and will have their bone marrow tested for MRD on Day 36 of cycle 1 and Day 36 of cycle 2 during treatment.

To evaluate the effectiveness of omecamtiv mecarbil in reducing the number of heart failure events or hospitalizations in patients with severely reduced left ventricular ejection fraction <30%.

Participate in about 13 in-person visits over 3 years with bloodwork at each in-person visit, participate in about 9 brief remote phone call visits, questionnaires at 5 of the in-person visits over the first year, first visit electrocardiogram (EKG), first visit Echocardiogram (ECHO) if not completed within the last 6 months, willing to be randomized to take oral study medication or placebo for the duration of the study (about 3 years).

Up to $1,500

This is a human–robot interaction study that will examine how well a robot can learn to perform a coffee-brewing task with help from a human user. Participants will physically correct the robot’s movements when the robot is moving in the wrong way, and will complete a short survey about their experience.

Participants will complete one in-person session. They will stand next to a robotic arm, guide the robot through a coffee-brewing task under different conditions, give physical interactions, and complete a short survey about their experience.

20

This study explores how human emotions influence the choices they make in an interactive game involving monetary prizes. Participants will play 5 repeated rounds of a two-player decision-making game where, in each round, they choose either to cooperate with the other player or act in their own self-interest. The amount of money they earn depends on both their own choice and the choice of the other player in each round. Participants will not be able to see the person that they are playing with because a divider will separate the two. They will also not be told that the other “player” is actually a member of the research team who follows a predetermined pattern of choices in the repeated game. Throughout the study, participants will answer brief questions on their phone about how they are feeling,and they will wear a wrist worn device that measures natural changes in skin conductance, which reflects emotional arousal. By combining these self-reported feelings with physiological signals, the study aims to understand how emotions related to repeated decisions involving cooperation, self interest and monetary incentives.

Participants will attend one in-person session (20-30 minutes). They will wear a wrist device that records skin conductance (EDA) and complete brief online surveys about their mood. They will play a multi-round decision-making game involving monetary earnings with another player. Earnings will depend on both players choices summed over the rounds.

$4-$28

This study aims to understand how parents make decisions about enrolling their child in an early phase or precision medicine cancer clinical trial. We will explore parents’ decision-making process, values, goals, and views of risks and benefits, as well as their psychosocial outcomes. Participants will be asked to complete a set of questionnaires, and they may choose to take part in an optional interview to discuss their decision-making in more depth. Please note that parents whose child was offered a upfront standard of care clinical trial at diagnosis (i.e., a phase III trial comparing treatments that are already accepted and evidence-based, rather than novel or experimental agents) are not be eligible to participate.

This study entails completing an anonymous questionnaire asking items related to you and your child’s demographic information, how you are doing on key psychosocial outcomes (e.g., psychological distress, anxiety, depression), your perceived moral obligation, your emotional expressivity and authenticity, your coping style, your level of trust in the provider, and your perceived social support. This survey may take up to 1 hour to complete. At the end of the questionnaire you will be asked if you would be interested in participating in a one-time 30-60 minute conversation to provide a more in depth discussion on these topics. If you are interested, a study team member will reach out to you to provide more information and have you sign a separate consent form for that part of the study.

This will compare Dato-Dxd against docetaxel in previously treated advanced or metastatic non squamous NSCLC.

the first visit will be to sign a consent form to test for a specific biomarker in your archived tumor. If you have that biomarker you will then sign a consent form to participate in the study, if you wish. You will need to come to the clinic for bloodwork and scans to make sure it is safe for you to participate. If it is determined that it is safe for you to continue, you will come to the clinic every month for treatment of your cancer. These visit may also include seeing the doctor, having blood work and completing questionnaires.

$1200.00 You will only be compensated for completed visits.

The main purpose of this clinical trial is to determine whether early non-invasive ventilation (NIV) in individuals diagnosed with amyotrophic lateral sclerosis (ALS) is feasible and is associated with improved quality of life, symptoms, and carbon dioxide levels compared to usual care. Study subjects assigned to the “early NIV” group will start NIV earlier than subjects in the usual care group. The study population will included a total of 48 adults diagnosed with ALS at three Neurology ALS clinics in the United States. Subjects will participate in a total of 5 study visits over a 12-month period.

Once eligible, enrolled subjects are assigned to a group (early NIV or usual care), they will attend a total of 5 in person study visits at the ALS clinic over a 12-month period. At Visit 1, subjects will complete questionnaires and assessments and receive the initial study intervention. Follow-up visits at the ALS clinic will take place every 3 months (Visit 2/Month 3; Visit 3/Month 6; Visit 4/Month 9; Visit 5/Month 12) with the completion of questionnaires and assessments plus review of NIV data as applicable.

The purpose of this clinical research study is to learn more about the use of the investigational drug, deucrictibant, for the prevention and treatment of Acquired Angioedema due to C1 Inhibitor Deficiency (AAE-C1INH) attacks. The study consists of a Screening Phase (up to 10 weeks), followed by a 12-weeks Prophylaxis Treatment Phase (Part 1), an On-demand Treatment Phase (Part 2) and an Open-Label On-demand Treatment Phase (Part 3). These are all described below. If you provide your consent to take part in the study and you are declared eligible to participate, your overall study participation will last approximately 15 months (60 weeks). During this study you will be asked to complete an electronic diary daily. At the study visits you will have blood samples collected. Vital signs, EKGs, and physical exams will be performed.

If you decide to take part in this research study, you will have a screening phase (up to 10 weeks), followed by a 12-week Prophylaxis Treatment Phase (Part 1), an On-demand Treatment Phase (Part 2) and an Open-Label On-demand Treatment Phase (Part 3). If you provide your consent to take part in the study and you are declared eligible to participate, your overall study participation will last approximately 15 months (60 weeks). where you will have procedures to determine if you meet the requirements to be in the study. These include a physical exam and an electrocardiogram (ECG) which will measure the electrical activity of your heart. You will also be required to give blood and urine samples. You will also need to complete a daily electronic diary. If you are a woman who can have children, you will also need to take pregnancy tests.

This study examines how speakers change their language use as they age. Sociolinguistic interviews will be used to document and analyze features of English in Pennsylvania. Sociolinguistic interviews will be conducted between the investigator(s) and the participant(s). Participants will be invited to complete the recorded interviews at different intervals in time. The hypothesis is that language use will change as a speaker ages - as social pressures and lifestyle change, so will language.

In this study, the interviewer will ask you a series of questions about your life. The following are some example topics you may be asked about: Personal background (e.g., place of birth, school, work, family, life in Pennsylvania), Leisure, media, everyday life (e.g., hobbies, dreams, sports and social events) Life experiences (e.g., favorite childhood memories, experience during Covid lockdown) Personal beliefs (e.g., spirituality, superstitions) Language (e.g., thoughts about language use and change) The interview will be audio recorded (no video). You will also be asked to complete a background questionnaire so that we can learn more about your life. When filling out the background questionnaire, you are free to skip any questions you prefer not to answer. At the end of the study, we may ask you if you would be interested in being contacted for follow-up interviews.

$20.00

To determine whether the addition of stereotactic ablative radiotherapy (SABR) to the primary tumor in combination with immunotherapy improves outcomes compared to immunotherapy alone in patients with metastatic, unresected, renal cell carcinoma (RCC).

The patient will either get immune therapy (either 2 immune therapy drugs or immune therapy plus a VEGF targeted therapy), or get immune therapy plus radiation therapy. The radiation treatments will be given on 3 different days over the course of 1-3 weeks. Immune therapy will continue until it is no longer working. After the treatment is stopped, the doctor and study team will monitor the patient every 6 months for 5 years after treatment and then annually for 3 years.

This study will look at the safety and effectiveness of cannabigerol (CBG)/cannabidiol (CBD) in the treatment of chemotherapy induced peripheral neuropathy.

You must attend all scheduled study visits, tell the study doctor about all medications you are taking (including over-the-counter medicines), and let the study team know how you are feeling. Patients must come to clinic visits (about every 4 weeks) for health checks, blood tests and surveys, take the hemp oil (CBG/CBD) twice a day for 12 weeks, complete a drug diary, return unused oil on their next visit, and answer phone calls between visits.

$500.00 if substudy completed

This research aims to investigate how memory functions in cognitively healthy individuals by characterizing age-related differences in memory performance and cognitive processes.

Individuals will be asked to complete computer-based and paper-and-pencil tasks with a researcher. These tasks are designed to assess memory and cognition during a single session. This session can be separated at the request of the participant.

$10/hour